126.35
price down icon0.15%   -0.19
pre-market  Pre-market:  126.42   0.07   +0.06%
loading
Abbott Laboratories stock is traded at $126.35, with a volume of 8.16M. It is down -0.15% in the last 24 hours and down -5.98% over the past month. Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
See More
Previous Close:
$126.54
Open:
$126.15
24h Volume:
8.16M
Relative Volume:
1.23
Market Cap:
$219.83B
Revenue:
$43.11B
Net Income/Loss:
$13.98B
P/E Ratio:
15.83
EPS:
7.98
Net Cash Flow:
$6.66B
1W Performance:
+1.55%
1M Performance:
-5.98%
6M Performance:
-0.82%
1Y Performance:
+20.06%
1-Day Range:
Value
$125.62
$126.99
1-Week Range:
Value
$124.22
$126.99
52-Week Range:
Value
$99.92
$140.84

Abbott Laboratories Stock (ABT) Company Profile

Name
Name
Abbott Laboratories
Name
Phone
(224) 667-6100
Name
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Name
Employee
114,000
Name
Twitter
@AbbottNews
Name
Next Earnings Date
2025-07-17
Name
Latest SEC Filings
Name
ABT's Discussions on Twitter

Compare ABT with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Medical Devices icon
ABT
Abbott Laboratories
126.35 220.16B 43.11B 13.98B 6.66B 7.98
Medical Devices icon
BSX
Boston Scientific Corp
105.84 157.03B 18.49B 2.51B 2.72B 1.68
Medical Devices icon
SYK
Stryker Corp
400.69 154.21B 23.22B 2.86B 3.58B 7.40
Medical Devices icon
MDT
Medtronic Plc
91.97 119.08B 33.54B 4.66B 5.19B 3.62
Medical Devices icon
EW
Edwards Lifesciences Corp
78.49 46.93B 5.69B 4.15B 623.10M 6.95

Abbott Laboratories Stock (ABT) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-18-25 Upgrade Jefferies Hold → Buy
Jun-16-25 Initiated Leerink Partners Market Perform
Oct-08-24 Initiated Oppenheimer Outperform
Sep-19-24 Initiated Piper Sandler Overweight
Jul-30-24 Downgrade Edward Jones Buy → Hold
May-30-24 Initiated Goldman Buy
Jul-21-23 Upgrade Wolfe Research Underperform → Peer Perform
May-30-23 Downgrade Morgan Stanley Overweight → Equal-Weight
Apr-20-23 Reiterated Barclays Overweight
Apr-20-23 Reiterated Bernstein Outperform
Apr-20-23 Reiterated JP Morgan Overweight
Apr-20-23 Reiterated Raymond James Outperform
Apr-20-23 Reiterated UBS Buy
Apr-20-23 Reiterated Wolfe Research Underperform
Mar-29-23 Initiated UBS Buy
Oct-26-22 Initiated Mizuho Neutral
Oct-18-22 Initiated Barclays Overweight
Oct-12-22 Initiated Jefferies Hold
Jul-06-22 Initiated Wolfe Research Underperform
Mar-02-22 Resumed BofA Securities Buy
Jan-27-22 Reiterated Credit Suisse Outperform
Jan-27-22 Reiterated Morgan Stanley Overweight
Jan-27-22 Reiterated Raymond James Outperform
Jan-27-22 Reiterated UBS Buy
Dec-10-21 Initiated RBC Capital Mkts Outperform
Oct-27-21 Upgrade Atlantic Equities Neutral → Overweight
Oct-14-21 Initiated Redburn Neutral
May-25-21 Initiated Barclays Overweight
Apr-15-21 Initiated Atlantic Equities Neutral
Jan-28-21 Upgrade BTIG Research Neutral → Buy
Sep-11-20 Initiated Wolfe Research Outperform
Jun-01-20 Downgrade Goldman Neutral → Sell
Mar-05-20 Initiated Citigroup Buy
Feb-13-20 Initiated Goldman Neutral
Feb-06-20 Resumed BTIG Research Neutral
Jan-02-20 Downgrade Guggenheim Buy → Neutral
Jun-13-19 Reiterated BofA/Merrill Buy
Feb-07-19 Reiterated BofA/Merrill Buy
Jan-02-19 Downgrade Citigroup Neutral → Sell
Nov-30-18 Upgrade Goldman Neutral → Buy
Oct-16-18 Initiated Barclays Overweight
Jun-27-18 Initiated Bernstein Outperform
Jan-30-18 Reiterated Citigroup Neutral
Jan-25-18 Reiterated Stifel Buy
Jan-25-18 Upgrade William Blair Mkt Perform → Outperform
Jan-03-18 Initiated Evercore ISI Outperform
Jan-02-18 Upgrade JP Morgan Neutral → Overweight
Jan-02-18 Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-19-17 Reiterated RBC Capital Mkts Outperform
Oct-19-17 Reiterated Stifel Buy
View All

Abbott Laboratories Stock (ABT) Latest News

pulisher
04:38 AM

Europe Defibrillator Market Forecast and Company Analysis Report 2025-2033 Featuring Medtronic, Philips, Nihon Kohden, Boston Scientific, Stryker, Asahi Kasei, LivaNova, and Abbott - GlobeNewswire Inc.

04:38 AM
pulisher
Jul 28, 2025

2nd Abbott Baby Formula Bellwether Falls Before Trial - Law360

Jul 28, 2025
pulisher
Jul 28, 2025

RBC Capital Sees Strong Growth Potential for Abbott Laboratories (ABT) - MSN

Jul 28, 2025
pulisher
Jul 28, 2025

Leerink Partners Decreases PT on Abbott Laboratories (ABT) to $136 From $143, Maintains a Hold Rating - Insider Monkey

Jul 28, 2025
pulisher
Jul 28, 2025

RBC Capital Bullish on Abbott Laboratories, Raises Price Target to $147. - AInvest

Jul 28, 2025
pulisher
Jul 27, 2025

Why is Abbott Laboratories stock attracting strong analyst attentionBuild wealth with steady, reliable stocks - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

Declining Stock and Solid Fundamentals: Is The Market Wrong About Abbott Laboratories (NYSE:ABT)? - Yahoo Finance

Jul 27, 2025
pulisher
Jul 26, 2025

Continental Express wins fifth Abbott award - Sidney Daily News

Jul 26, 2025
pulisher
Jul 26, 2025

Did Strong Q2 Results and Raised Guidance Just Shift Abbott Laboratories' (ABT) Investment Narrative? - simplywall.st

Jul 26, 2025
pulisher
Jul 26, 2025

Oversold Abbott Laboratories (ABT) Could Offer a Healthy Dividend Opportunity - MSN

Jul 26, 2025
pulisher
Jul 25, 2025

What analysts say about Abbott Laboratories stockConsistent high-performance stocks - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

Abbott Laboratories Stock Analysis and ForecastDynamic growth stocks - Autocar Professional

Jul 25, 2025
pulisher
Jul 24, 2025

What drives Abbott Laboratories stock priceOutstanding capital appreciation - Autocar Professional

Jul 24, 2025
pulisher
Jul 24, 2025

Abbott Laboratories (ABT): A Bull Case Theory - MSN

Jul 24, 2025
pulisher
Jul 24, 2025

The Zacks Analyst Blog Highlights Wells Fargo, Abbott Laboratories, American Express, TSS and Maui Land & Pineapple - Yahoo Finance

Jul 24, 2025
pulisher
Jul 23, 2025

Abbott Laboratories (ABT): I Am Very Upset With Abbott,” Says Jim Cramer - MSN

Jul 23, 2025
pulisher
Jul 23, 2025

Top Stock Reports for Wells Fargo, Abbott & American Express - Yahoo Finance

Jul 23, 2025
pulisher
Jul 23, 2025

Brianne Gardner's Top Picks: Abbott Labs, Chipotle Mexican Grill & Motorola Solutions - BNN Bloomberg

Jul 23, 2025
pulisher
Jul 23, 2025

Jim Cramer Says He “Was Discouraged to Get a Mixed Update from Abbott Labs” - MSN

Jul 23, 2025
pulisher
Jul 23, 2025

Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know - Yahoo Finance

Jul 23, 2025
pulisher
Jul 23, 2025

Institutional owners may ignore Abbott Laboratories' (NYSE:ABT) recent US$10b market cap decline as longer-term profits stay in the green - Yahoo Finance

Jul 23, 2025
pulisher
Jul 23, 2025

Notable healthcare headlines for the week: Trump’s tariff threats, J&J, Abbott Laboratories and Sarepta in focus - MSN

Jul 23, 2025
pulisher
Jul 22, 2025

Abbott Laboratories stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch

Jul 22, 2025
pulisher
Jul 22, 2025

Canada Oncology Market Outlook to 2033 - GlobeNewswire Inc.

Jul 22, 2025
pulisher
Jul 22, 2025

Abbott Laboratories (NYSE:ABT) Q2 2025 Earnings Call Transcript - MSN

Jul 22, 2025
pulisher
Jul 22, 2025

Low-Calorie Food Market Top Companies StudyAbbott - openPR.com

Jul 22, 2025
pulisher
Jul 21, 2025

NEC Baby Formula Lawsuit & Settlement | July 2025 Update - Lawsuit Information Center

Jul 21, 2025
pulisher
Jul 21, 2025

Estimating The Fair Value Of Abbott Laboratories (NYSE:ABT) - 富途牛牛

Jul 21, 2025
pulisher
Jul 21, 2025

Abbott Laboratories: Hold Rating Amid Mixed Performance and Sector Challenges - TipRanks

Jul 21, 2025
pulisher
Jul 21, 2025

Abbott Labs stock rating reiterated at Buy by UBS despite guidance cut - Investing.com India

Jul 21, 2025
pulisher
Jul 20, 2025

Abbott Laboratories falls after setting Q3 outlook below consensus - MSN

Jul 20, 2025
pulisher
Jul 20, 2025

Abbott Laboratories Stock (ABT) Opinions on Q2 Earnings and Guidance Update - Quiver Quantitative

Jul 20, 2025
pulisher
Jul 19, 2025

Is Abbott Laboratories (ABT) a Buy After the Earnings Selloff? - AInvest

Jul 19, 2025
pulisher
Jul 19, 2025

Abbott Drops After Lowering Top End of Full-Year Guidance - MSN

Jul 19, 2025
pulisher
Jul 19, 2025

Abbott Laboratories: A Medtech Titan Positioned for Growth in a Transformed Healthcare Landscape - AInvest

Jul 19, 2025
pulisher
Jul 19, 2025

Abbott Laboratories Second Quarter 2025 Earnings: EPS Beats Expectations - Yahoo Finance

Jul 19, 2025
pulisher
Jul 19, 2025

Abbott Laboratories Sheds Nearly 5% On A Rare Guidance Miss - MSN

Jul 19, 2025
pulisher
Jul 19, 2025

A Quick Look at Today's Ratings for Abbott Laboratories(ABT.US), With a Forecast Between $135 to $159 - 富途牛牛

Jul 19, 2025

Abbott Laboratories Stock (ABT) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
medical_devices BSX
$105.84
price down icon 0.28%
medical_devices SYK
$400.69
price down icon 0.70%
medical_devices MDT
$91.97
price down icon 1.04%
medical_devices EW
$78.49
price down icon 1.89%
$77.74
price up icon 0.17%
Cap:     |  Volume (24h):